Nimbus Therapeutics has reported positive data from a Phase IIb clinical trial of NDI-034858, an allosteric TYK2 inhibitor, in moderate-to-severe plaque psoriasis patients.

The double-blind, multicentre, placebo-controlled, randomised study was designed for evaluating the tolerability, safety, and efficacy of four doses of NDI-034858 given orally once a day to psoriasis patients.

Findings from 259 trial participants showed that the allosteric TYK2 inhibitor achieved statistical significance, with a greater number of patients reaching PASI-75, compared to a placebo at 12 weeks.

The company stated that NDI-034858 has also achieved additional endpoints in the study, and its safety was consistent with other allosteric TYK2 inhibitors.

It intends to present this trial data at an upcoming medical conference.

Nimbus Clinical Development senior vice-president Bhaskar Srivastava said: “We are pleased to report success from our Phase 2b psoriasis patient trial that supports NDI-034858’s best-in-class potential among the new class of allosteric TYK2 inhibitors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Additionally, the consistent safety profile seen in this study reinforces TYK2 inhibitors as a differentiated non-JAK therapeutic class.”

The company stated that NDI-034858 is being assessed to treat several autoimmune diseases.

It showed wide therapeutic margins and exceptional functional selectivity in preclinical studies.

The therapy is currently being evaluated in an ongoing Phase IIb trial in active psoriatic arthritis patients, in addition to psoriasis.

Nimbus plans to launch the Phase III studies in psoriasis, as well as the future trials in other autoimmune indications such as inflammatory bowel disease (IBD) and lupus.

Last November, the company dosed the first participant in its Phase I/II trial of NDI-101150 in solid tumour patients.